BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Post-Mkt 06-26 16:55:11 EDT

279.89

+4.55

+1.65%

盘后279.89

+0.000.00%

16:10 EDT

High283.80	Low272.75	Vol336.79K
Open275.00	D1 Closing275.34	Amplitude4.01%
Mkt Cap33.31B	Tradable Cap23.92B	Total Shares119.00M
T/O94.06M	T/O Rate0.39%	Tradable Shares85.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":279.89,"timestamp":1782504000000,"preClose":275.34,"halted":0,"volume":336791,"hourTrading":{"tag":"盘后","latestPrice":279.89,"preClose":279.89,"latestTime":"16:10 EDT","volume":873,"amount":244343.97,"timestamp":1782504605188,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016525023607176625,"floatShares":85446200,"shares":119000000,"eps":4.404108,"marketStatus":"Post-Mkt","change":4.55,"latestTime":"06-26 16:55:11 EDT","open":275,"high":283.8,"low":272.75,"amount":94055439,"amplitude":0.040132,"askPrice":284,"askSize":7,"bidPrice":274.49,"bidSize":7,"shortable":3,"etf":0,"ttmEps":4.404108,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782518400000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":275.34,"preHourTrading":{"tag":"盘前","latestPrice":275,"preClose":275.34,"latestTime":"07:15 EDT","volume":41,"amount":11274.561300000001,"timestamp":1782472533665,"change":-0.34,"changeRate":-0.001235,"amplitude":0.003523},"postHourTrading":{"tag":"盘后","latestPrice":279.89,"preClose":279.89,"latestTime":"16:10 EDT","volume":873,"amount":244343.97,"timestamp":1782504605188,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.242739,"impliedVol":0.3957,"impliedVolPercentile":0.1633},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"1125815089","title":"BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved","url":"https://stock-news.laohu8.com/highlight/detail?id=1125815089","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125815089?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:08","pubTimestamp":1782468514,"startTime":"0","endTime":"0","summary":"BEIGENE (ASX: 06160) has announced that a wholly-owned subsidiary in China has received and agreed to a notice from local tax authorities regarding adjustments to previously filed tax returns.The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4526","LU2328871848.SGD","BK1500","BK4139","BK1588","LU1251922891.USD","LU1770034418.SGD","ONC","688235","LU1303224171.USD","BK1161","LU0307460666.USD","BK1583","LU1719994722.HKD","LU1969619763.USD","LU0588546209.SGD","06160","BK0239","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646802037","title":"BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802037?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405082,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running an observational study called “A Real-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ONC","BK4526","BK4139","BK4585","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808016","title":"BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808016?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800347,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4585","ISBC","MDCO","BK4588","BK4526","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644809090","title":"BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644809090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644809090?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800331,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1a/1b study, officially titled “Phase 1a/1b Randomized Study ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","MDCO","BK4585","BK4526","ONC","BK4211","BK4139","BK4588","BGB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162658338","title":"BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162658338","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162658338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:21","pubTimestamp":1781788869,"startTime":"0","endTime":"0","summary":"The pharmaceutical company BEIGENE (06160) has disclosed the granting of share-based awards to certain recipients.On June 11, 2026, the board of directors, the compensation committee, and/or the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1770034418.SGD","BK4588","BK0239","BK1500","LU0307460666.USD","LU2328871848.SGD","BK4585","BK1588","BK1583","LU1969619763.USD","LU0588546209.SGD","BK4139","BK1161","LU1251922891.USD","ONC","LU1719994722.HKD","LU1303224171.USD","688235","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644370681","title":"BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644370681","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644370681?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:39","pubTimestamp":1781771940,"startTime":"0","endTime":"0","summary":"0839 GMT - BeOne Medicine's revenue is forecast to reach $6.5 billion in 2026, driven by flagship cancer drug Brukinsa, which helped turn its operating margins positive last year, Morningstar analyst Kai Wang says. He sees the stock as undervalued, citing potential sales growth of its chronic lymphocytic leukemia treatment Brukinsa and its other core product Beqalzi, which is projected to generate $1 billion in sales by 2035. Wang estimates margin expansion of 400 basis points over the long term, as Brukinsa continues to scale out and capture more market share. Beyond 2026, Morningstar forecasts Brukinsa revenue growth in the high teens annually before slowing to 6% by 2032, when its patent expires. It initiates coverage of BeOne's H-shares with a fair value estimate of HK$214. The stock closed at HK$163.70. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","BK4526","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728385","title":"BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728385","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728385?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:32","pubTimestamp":1781713967,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running a Phase 1 study called “An Open-Label,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BGB","BK4588","ONC","BK4526","BK4139","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276720","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643276720?lang=en_us&edition=fundamental","pubTime":"2026-06-15 16:37","pubTimestamp":1781512665,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. According to Tip...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139","BK4526","MDCO","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267757","title":"BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267757?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:21","pubTimestamp":1781263301,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Friday that new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed \"durable responses\" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.Data from 67 patients with relapsed or refractory CLL/SLL treated with tacabrutideg across multiple dose levels showed an overall response rate of 85.1% and a 24-month progression-free survival rate of 53.8%. BeOne said tacabrutideg was generally well tolerated and no new toxicities were identified.In patients with relapsed or refractory Waldenstrom macroglobulinemia, tacabrutideg achieved a major response rate of 76.3%, a very good partial response rate of 30.2% and a 15-month progression-free survival rate of 70.4%.The data were announced at the European Hematology Association Congress in Stockholm.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4139","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281672","title":"BeOne Medicines announces presentation of Phase 3 data in CLL patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281672?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:40","pubTimestamp":1781178008,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-announces-presentation-of-phase-3-data-in-cll-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-announces-presentation-of-phase-3-data-in-cll-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4526","MDCO","ONC","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162679995","title":"BEIGENE Announces Grant of Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162679995","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162679995?lang=en_us&edition=fundamental","pubTime":"2026-06-05 17:16","pubTimestamp":1780650982,"startTime":"0","endTime":"0","summary":"BEIGENE (HKEX: 06160) has issued an announcement regarding a grant of restricted share units.On June 1, 2026, the Board's Compensation Committee, in accordance with the terms of the 2016 Option and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688235","BK1583","LU0588546209.SGD","BK4526","BK4139","LU1770034418.SGD","BK1500","06160","LU1251922891.USD","BK1588","LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","ONC","LU1969619763.USD","BK4588","BK0239","BK4585","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640186410","title":"Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640186410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640186410?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:00","pubTimestamp":1780509641,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","RGEN","MDCO","XBI","LU0106261612.USD","LU0757428866.USD","LABU","LU0053671581.USD","LU1815336091.USD","BK4585","BK4588","LU0012050646.USD","PCVX","BK4581","ONC","BK4139","XLV","LU0029874061.USD","BK4526","BK4121","HCSG","LU0128526141.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972140","title":"Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640972140?lang=en_us&edition=fundamental","pubTime":"2026-06-03 16:17","pubTimestamp":1780474659,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. Darout covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640463941","title":"BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2640463941","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640463941?lang=en_us&edition=fundamental","pubTime":"2026-06-02 23:04","pubTimestamp":1780412648,"startTime":"0","endTime":"0","summary":"BeOne Medicines  reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.\"While more data, and in some cases, optimization is still needed, we th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK4139","BK4526","ONC","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943710","title":"Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943710?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:00","pubTimestamp":1780405239,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeOne Medicines (ONC), Moderna (MRNA) and Danaher ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-beone-medicines-onc-moderna-mrna-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-beone-medicines-onc-moderna-mrna-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000M9KFDE8.USD","BK4533","LU0128526141.USD","BK4548","LU1023059063.AUD","BK4139","LU1974910355.USD","LU0157215616.USD","LU2265009873.SGD","BK4585","MRNA","LU0820562030.AUD","ONC","LU1791710400.SGD","IE00BQXX3D17.EUR","LU0511384066.AUD","LU1057294990.SGD","LU1791710582.SGD","IE00BKVL7J92.USD","XBI","MDCO","LU2125910336.SGD","DHR","LU0708995401.HKD","LU0175139822.USD","LU0820561818.USD","LU2125909247.SGD","BK4588","LU2112291526.USD","LU1267930730.SGD","IE0004445239.USD","SG9999013999.USD","XLV","LU0029874061.USD","LU1366333091.USD","MRNX","LU0528227936.USD","LU0882574055.USD","LU0320765059.SGD","BK4551","LU0097036916.USD","HCSG","LABU","LU2125910179.SGD","SGXZ23171101.USD","BK4568","LU0820561909.HKD","LU0107464264.USD","LU1923622614.USD","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943011","title":"TD Cowen Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943011?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:58","pubTimestamp":1780405082,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on BeOne Medicines, with a price target of $424.00. Werber covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","BK4207","BK4585","BK4588","TD","BK4526","MDCO","BK4139","ONC","BK4127","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294332","title":"Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294332?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404062,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","HCSG","BK4526","AMIX","BLRX","LABU","LU0128526141.USD","XLV","MDCO","BK4581","BK4139","BK4585","XBI","BK4082","BK4137","BK4588","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910589","title":"RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910589?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:40","pubTimestamp":1780400423,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines today and set a price target of $436.00. According to TipRanks, Tima...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640997218","title":"Beone Medicines : RBC Raises Target Price to $436 From $425","url":"https://stock-news.laohu8.com/highlight/detail?id=2640997218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640997218?lang=en_us&edition=fundamental","pubTime":"2026-06-02 14:32","pubTimestamp":1780381950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A03G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONC","BK4585","688235","BK4588","BK4526","BK4139","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955081","title":"BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955081","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955081?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:10","pubTimestamp":1780312221,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4526","MDCO","BK4588","ONC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":-0.0896},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.1186},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.0937}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.019621},{"month":6,"riseRate":0.454545,"avgChangeRate":0.007362},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction